TNF and rheumatoid arthritis: TNF-α inhibitors (infliximab), anti-IL-1 receptors (Anakinra), and anti-IL-6 receptors (tocilizumab), are amongst available biologic agents used to target specific mediators in RA angiogenesis [11, 12].